ATE495240T1 - Ligand des zelleintritt-vermittelnden proteins von herpes simplex virus und methoden zu dessen verwendung - Google Patents

Ligand des zelleintritt-vermittelnden proteins von herpes simplex virus und methoden zu dessen verwendung

Info

Publication number
ATE495240T1
ATE495240T1 AT98933153T AT98933153T ATE495240T1 AT E495240 T1 ATE495240 T1 AT E495240T1 AT 98933153 T AT98933153 T AT 98933153T AT 98933153 T AT98933153 T AT 98933153T AT E495240 T1 ATE495240 T1 AT E495240T1
Authority
AT
Austria
Prior art keywords
methods
herpes simplex
simplex virus
cell entry
protein ligand
Prior art date
Application number
AT98933153T
Other languages
German (de)
English (en)
Inventor
Carl Ware
Original Assignee
Jolla Inst Allergy Immunolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Inst Allergy Immunolog filed Critical Jolla Inst Allergy Immunolog
Application granted granted Critical
Publication of ATE495240T1 publication Critical patent/ATE495240T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
AT98933153T 1997-07-07 1998-07-07 Ligand des zelleintritt-vermittelnden proteins von herpes simplex virus und methoden zu dessen verwendung ATE495240T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5196497P 1997-07-07 1997-07-07
US08/898,234 US6140467A (en) 1997-07-07 1997-07-30 Ligand for herpes simplex virus entry mediator and methods of use
PCT/US1998/013897 WO1999002563A1 (en) 1997-07-07 1998-07-07 Ligand for herpes simplex virus entry mediator and methods of use

Publications (1)

Publication Number Publication Date
ATE495240T1 true ATE495240T1 (de) 2011-01-15

Family

ID=26730006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98933153T ATE495240T1 (de) 1997-07-07 1998-07-07 Ligand des zelleintritt-vermittelnden proteins von herpes simplex virus und methoden zu dessen verwendung

Country Status (11)

Country Link
US (1) US6140467A (cg-RX-API-DMAC7.html)
EP (1) EP1003782B1 (cg-RX-API-DMAC7.html)
JP (1) JP4712966B2 (cg-RX-API-DMAC7.html)
KR (1) KR100620334B1 (cg-RX-API-DMAC7.html)
CN (2) CN1891714B (cg-RX-API-DMAC7.html)
AT (1) ATE495240T1 (cg-RX-API-DMAC7.html)
AU (1) AU741419B2 (cg-RX-API-DMAC7.html)
CA (1) CA2296737C (cg-RX-API-DMAC7.html)
DE (1) DE69842096D1 (cg-RX-API-DMAC7.html)
TW (1) TWI222453B (cg-RX-API-DMAC7.html)
WO (1) WO1999002563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
WO2000010591A1 (en) * 1998-08-18 2000-03-02 The Trustees Of The University Of Pennsylvania Peptides for inhibition of herpes simplex virus entry
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
AU2007201279B2 (en) * 2000-03-13 2011-05-26 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
ATE365214T1 (de) 2000-04-12 2007-07-15 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
WO2002032463A1 (en) * 2000-10-18 2002-04-25 Smithkline Beecham Corporation Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules
US7514407B2 (en) * 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
ATE382372T1 (de) * 2003-06-11 2008-01-15 Univ Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
WO2008098183A2 (en) * 2007-02-08 2008-08-14 The University Of Chicago Combination therapy for treating cancer
JP2012507299A (ja) * 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Light標的分子およびその使用
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
CN107213456B (zh) * 2017-05-25 2020-08-21 苏州华测生物技术有限公司 淋巴毒素衍生物的新用途
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
CA3173873A1 (en) 2020-04-01 2021-10-07 Avalo Therapeutics, Inc. Methods and treatment involving excess free light
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298711B6 (cs) * 1995-01-26 2008-01-02 Biogen Idec Ma Inc. Farmaceutické prostredky aktivující LT-beta receptor pro lécení nebo omezení pokracování, závažnosti nebo úcinku neoplazie, zpusob selekce LT-beta receptor aktivujícího cinidla a protilátky proti LT-beta receptoru
AU2363695A (en) * 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
EP0904278A4 (en) * 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
WO1998003648A1 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
JP4090092B2 (ja) * 1996-07-19 2008-05-28 武田薬品工業株式会社 新規Fasリガンド様タンパク質およびそのDNA
BR9712670A (pt) * 1996-10-25 1999-10-19 Biogen Inc Receptores para linfotoxina-beta, anticorpos anti-receptor para linfotoxina, e anticorpos antiligante de linfotoxina como agentes terapêuticos para o tratamento de doencas imunológicas
WO1998018824A1 (en) * 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
JP2001524985A (ja) * 1997-05-12 2001-12-04 スミスクライン・ビーチャム・コーポレイション ヒト腫瘍壊死因子受容体様2(tr2)抗体
US6346388B1 (en) * 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
US6051385A (en) * 1997-10-22 2000-04-18 The Regents Of The University Of Michigan Compositions and methods for identifying and testing therapeutics against HSV infection
AU2972199A (en) * 1998-02-20 1999-09-06 Reinhard Ebner Apoptosis inducing molecule ii and methods of use

Also Published As

Publication number Publication date
CA2296737C (en) 2012-07-03
US6140467A (en) 2000-10-31
EP1003782B1 (en) 2011-01-12
CN1268953A (zh) 2000-10-04
CN1891714B (zh) 2011-06-22
AU8288298A (en) 1999-02-08
HK1026913A1 (en) 2000-12-29
EP1003782A1 (en) 2000-05-31
EP1003782A4 (en) 2002-07-10
AU741419B2 (en) 2001-11-29
WO1999002563A1 (en) 1999-01-21
KR20010021579A (ko) 2001-03-15
TWI222453B (en) 2004-10-21
JP4712966B2 (ja) 2011-06-29
DE69842096D1 (de) 2011-02-24
CA2296737A1 (en) 1999-01-21
KR100620334B1 (ko) 2006-09-13
CN1891714A (zh) 2007-01-10
JP2001509373A (ja) 2001-07-24

Similar Documents

Publication Publication Date Title
DE69842096D1 (de) Ligand des zelleintritt-vermittelnden proteins von herpes simplex virus und methoden zu dessen verwendung
ATE172984T1 (de) Nukleinsäuren-bindende oligomere mit n- verzweigung für therapie und diagnostik
DE69321218D1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
TR199902124T2 (xx) �ltihapl� hastal�klar�n tedavisinde yararl� k���k molek�ller.
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
DE69833160D1 (de) Amplifizierung und Detektion von HIV-1 und/oder HIV-2
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EP0861262A4 (en) GROUPS FOR CATCHING NUCLEIC ACIDS
FR2703693B1 (fr) Procédé rapide de détermination d'une séquence d'ADN et application au séquençage et au diagnostic.
ATE268385T1 (de) Mykrobakterielle proteine, mikroorganismen welche diese produzieren und ihre verwendung als impfstoff und zum nachweis von zuberkulose
DE60038993D1 (de) Oligonukleotidprimer zur reversen Transkription für den effizienten Nachweis von HIV-1 und HIV-2 und Methoden ihrer Verwendung
ATE315643T1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE69316948D1 (de) Lösliche Liganden für CD40
ATE180494T1 (de) Nukleinsäure-bindende oligomere mit c-verzweigung für therapie und diagnostik
CY1111293T1 (el) Συνδετης για μεσολαβητη εισοδου του ιου του απλου ερπητα και μεθοδοι χρησης
EP1012603A4 (en) FUNCTIONAL FRAGMENTS OF THE HIV-1 VPR PROTEIN AND A METHOD FOR ITS USE
NO973875L (no) Fremgangsmåte for stimulering av en immunrespons
DK0981601T3 (da) Fremgangsmåder til dyrkning af celler og opformering af vira
WO2001079496A3 (en) Ligand for herpes simplex virus entry mediator and methods of use
FI953640L (fi) Termostabiilit ksylanaasi-DNA, proteiini ja käyttömenetelmät
WO1998049333A3 (en) Eukaryotic gene expression cassette and uses thereof
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DE69130845D1 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
DE69737891D1 (de) Verwendung von immuntherapeutischem wirkstoff auf peptidbasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties